No Abstract BioWorld International CorrespondentIntercell AG is strengthening an already solid cash position of €139.7 million (US$203 million) by immediately adding another €62 million, thanks to a wide-ranging strategic alliance with the GSK Biologicials arm of GlaxoSmithKline plc, based on its needle-free, patch-based vaccine in development for travelers' diarrhea and its enhancement patch for pandemic flu vaccines. It also stands to gain a share of the profits from global sales of the two products.

Shares in Movetis NV edged up slightly on their first day of trading on the NYSE Euronext Exchange in Brussels Friday, following an IPO that raised gross proceeds of €85 million (US$126 million). The company priced the offering of 6,938,776 new shares at €12.25, slightly below the mid-point of the indicative range of €11.25 to €14.25 it published at the outset of the book-building period. (BioWorld International) 

No Abstract BioWorld International CorrespondentLONDON - Biocompatibles International plc moved onto the next stage of its collaboration with AstraZeneca plc, agreeing to a schedule for the Phase I and Phase II trials of the Type II diabetes drug CM3, and thus triggering a further €4.3 million (US$6.4 million) payment from the pharma company.